3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
5
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
41
Carcinoma, Renal Cell
32
Neuroendocrine Tumors
15
Neoplasms
12
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
8
Carcinoma
7
Tuberous Sclerosis
6
Kidney Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoid Tumor
5
Lymphoma
4
Adenoma, Islet Cell
4
Stomach Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell
3
Lymphangioleiomyomatosis
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Angiomyolipoma
3
Adenocarcinoma
3
von Hippel-Lindau Disease
2
Triple Negative Breast Neoplasms
2
Seizures
2
Neuroectodermal Tumors, Primitive
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Interventions
Fulvestrant
9
Alpelisib
6
Letrozole
4
serabelisib
3
ribociclib
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
Cetuximab
3
sapanisertib
2
pembrolizumab
2
parsaclisib
2
binimetinib
2
Topotecan
2
NVP-BKM120
2
Irinotecan
2
Gemcitabine
2
venetoclax
1
tipifarnib
1
talazoparib
1
sotorasib
1
ruxolitinib
1
olaparib
1
obinutuzumab
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
gedatolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hereditary Sensory and Autonomic Neuropathies
×
Everolimus
×
Clear all
NCT00790400
2017-02-17
EXIST-2
Novartis
Phase 3
Completed
118 enrolled
15 charts